The National Tuberculosis and Leprosy Programme (NTLP) of Tanzania introduced the short treatment regimen for drug-sensitive TB, that includes rifampicin for the full 6 months, in 2006. Realizing that it would not to be able to sustain daily directly observed therapy (DOT) by a health professional, it embarked on a strategy to allow treatment supporters to observe treatment intake outside the direct health system.
The project describes the full cycle of assessing preference of patients, evaluation of the intervention, and monitoring implementation on the ground.CB-DOT is now an integral part of tuberculosis treatment delivery in Tanzania.
Funding: Novartis Foundation for Sustainable Development (NFSD)
Project partners: NTLP Tanzania; NFSD; National Institute for Medical Research (NIMR), Tanzania; KNCV Tuberculosis Foundation, the Netherlands
Timing: 2005 - 2012
